Compare FICO & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FICO | BIIB |
|---|---|---|
| Founded | 1956 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.8B | 27.3B |
| IPO Year | 1995 | 1996 |
| Metric | FICO | BIIB |
|---|---|---|
| Price | $1,260.53 | $215.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 25 |
| Target Price | ★ $1,689.92 | $206.83 |
| AVG Volume (30 Days) | 300.9K | ★ 1.0M |
| Earning Date | 04-28-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.78 | N/A |
| EPS | ★ 17.73 | 2.15 |
| Revenue | $1,032,475,000.00 | ★ $9,890,600,000.00 |
| Revenue This Year | $27.28 | N/A |
| Revenue Next Year | $16.97 | N/A |
| P/E Ratio | ★ $68.08 | $97.60 |
| Revenue Growth | N/A | ★ 2.22 |
| 52 Week Low | $870.01 | $121.06 |
| 52 Week High | $1,998.01 | $219.72 |
| Indicator | FICO | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 64.31 | 64.13 |
| Support Level | $1,193.10 | $170.52 |
| Resistance Level | $1,323.35 | N/A |
| Average True Range (ATR) | 46.04 | 6.51 |
| MACD | 8.38 | 1.47 |
| Stochastic Oscillator | 95.15 | 81.38 |
Founded in 1956, Fair Isaac Corporation is a leading applied analytics company. Fair Isaac is primarily known for its FICO credit scores, which is a widely used industry benchmark to determine the creditworthiness of an individual consumer. The firm's US-centric credit scores business accounts for most of the firm's revenue and profits and consists of business-to-business and business-to-consumer services. In addition to scores, Fair Isaac also sells software primarily to financial institutions for areas such as analytics, decision-making, customer workflows, and fraud.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).